These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32059745)

  • 1. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer.
    Galle E; Thienpont B; Cappuyns S; Venken T; Busschaert P; Van Haele M; Van Cutsem E; Roskams T; van Pelt J; Verslype C; Dekervel J; Lambrechts D
    Clin Epigenetics; 2020 Feb; 12(1):27. PubMed ID: 32059745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
    Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
    Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
    Lin SH; Wang J; Saintigny P; Wu CC; Giri U; Zhang J; Menju T; Diao L; Byers L; Weinstein JN; Coombes KR; Girard L; Komaki R; Wistuba II; Date H; Minna JD; Heymach JV
    BMC Genomics; 2014 Dec; 15(1):1079. PubMed ID: 25486910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
    Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
    Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
    Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma.
    Zhang PF; Wang F; Wu J; Wu Y; Huang W; Liu D; Huang XY; Zhang XM; Ke AW
    J Cell Physiol; 2019 Mar; 234(3):2788-2794. PubMed ID: 30132868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
    Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
    Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
    Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation of miR-200 clusters promotes epithelial to mesenchymal transition in human conjunctival epithelial cells.
    Rajić J; Dinić S; Uskoković A; Arambašić Jovanović J; Tolić A; Đorđević M; Đorđević M; Poznanović G; Mihailović M; Inic-Kanada A; Barisani-Asenbauer T; Grdović N; Vidaković M
    Exp Eye Res; 2020 Aug; 197():108047. PubMed ID: 32387379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
    Yu M; Han G; Qi B; Wu X
    Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S
    Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin C enhances epigenetic modifications induced by 5-azacytidine and cell cycle arrest in the hepatocellular carcinoma cell lines HLE and Huh7.
    Sajadian SO; Tripura C; Samani FS; Ruoss M; Dooley S; Baharvand H; Nussler AK
    Clin Epigenetics; 2016; 8():46. PubMed ID: 27134688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.
    Xia S; Pan Y; Liang Y; Xu J; Cai X
    EBioMedicine; 2020 Jan; 51():102610. PubMed ID: 31918403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
    Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
    Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.